Health Care & Life Sciences » Biotechnology | Cancer Genetics Inc.

Cancer Genetics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
49,459.60
25,554.10
19,459.00
9,502.00
9,541.00
161
Total Accounts Receivable
1,638.90
5,028.60
6,621.00
11,748.00
10,958.00
7,038
Inventories
198.80
279.90
133.00
146.00
144.00
144
Other Current Assets
594.00
911.30
1,985.00
2,028.00
2,563.00
2,004
Total Current Assets
51,891.20
31,773.90
28,198.00
23,424.00
23,206.00
9,347
Net Property, Plant & Equipment
1,264.60
4,446.60
6,069.00
4,738.00
5,550.00
4,056
Total Investments and Advances
1,263.70
7,386.20
641.00
568.00
596.00
442
Long-Term Note Receivable
24.00
-
10.00
10.00
10.00
-
Intangible Assets
401.70
3,496.90
13,756.00
13,532.00
22,470.00
21,261
Other Assets
312.10
1.60
210.00
162.00
389.00
300
Total Assets
55,157.30
47,105.10
48,884.00
42,434.00
52,221.00
35,406
ST Debt & Current Portion LT Debt
6,073.70
59.00
1,455.00
2,109.00
10,409.00
Accounts Payable
2,046.20
3,762.60
7,579.00
8,148.00
8,715.00
Other Current Liabilities
499.60
544.40
831.00
789.00
516.00
Total Current Liabilities
8,619.50
4,366.00
9,865.00
11,046.00
19,640.00
Long-Term Debt
309.80
6,860.70
4,918.00
3,028.00
624.00
Other Liabilities
764.80
1,324.70
1,084.00
2,736.00
5,192.00
Total Liabilities
9,694.10
12,551.40
15,867.00
16,810.00
25,456.00
Common Equity (Total)
45,463.20
34,553.80
33,017.00
25,624.00
26,765.00
Total Shareholders' Equity
45,463.20
34,553.80
33,017.00
25,624.00
26,765.00
Total Equity
45,463.20
34,553.80
33,017.00
25,624.00
26,765.00
Liabilities & Shareholders' Equity
55,157.30
47,105.10
48,884.00
42,434.00
52,221.00

About Cancer Genetics

View Profile
Address
Meadows Office Complex
Rutherford New Jersey 07070
United States
Employees -
Website http://www.cancergenetics.com
Updated 07/08/2019
Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.